Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Teva pharmaceutical industries ltd crawled date : 2022 - 09 - 15 save search
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Published: 2022-09-15 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
dupixent children lancet dermatitis positive
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Quinidine Sulfate Market Size to Grow by USD 427.29 mn, North America to be Largest Contributor to Market Growth - Technavio
Published: 2022-09-15 (Crawled : 12:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
america growth market
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.